Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Tenax Therapeutics, Inc.NASDAQ: TENX
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 6.6% from a year ago
Cash & equivalents stood at $118.76M at the end of Q1 FY2026, up 6.6% from a year earlier and up 21.7% from the prior quarter. Over 3 fiscal years it compounded at +258.2% a year.
Context
- Cash & equivalents amounted to 96.4% of total assets at the end of Q1 FY2026, down 3.0 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +6.6% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 97.57M USD
- Year-over-year change
- +2.9%
- 4-year CAGR
- +104.5%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97.57M | +2.9% |
| FY2024 | 2024-12-31 | 94.85M | +868.6% |
| FY2023 | 2023-12-31 | 9.79M | +361.1% |
| FY2022 | 2022-12-31 | 2.12M | -62.0% |
| FY2021 | 2021-12-31 | 5.58M | — |
Cash & Equivalents vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 cash & equivalents of $118.76M is the 2nd highest of the 7 companies compared; the peer median is $35.68M.
- Its year-over-year change of +6.6% is the 5th highest of 7, against a peer median of +69.8%.
- Cash & equivalents amounts to 96.4% of total assets for TENX, versus a peer median of 39.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $24.65B | +161575.2% | +31.6% | 25.9% | |
| Mar 2026 | $118.76M | +6.6% | +258.2% | 96.4% | |
| Mar 2026 | $53.49M | +167.6% | -9.9% | 61.1% | |
| Mar 2026 | $50.75M | -22.5% | +3.2% | 79.7% | |
| Mar 2026 | $20.6M | -30.4% | -4.2% | 53.1% | |
| Mar 2026 | $17.48M | +15.7% | +17.7% | 12.4% | |
| Jun 2026 | $8.27M | +123.9% | -11.3% | 3.5% | |
| Peer median (excluding TENX) | $35.68M | +69.8% | -0.5% | 39.5% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.